Vectura
| File:Vectura Group logo.png | |
| Company type | Public (LSE: VEC) |
|---|---|
| Industry | Pharmaceuticals |
| Founded | 1999 |
| Headquarters | Chippenham, UK |
Key people | Bruno Angelici, Chairman Christopher Blackwell, (CEO) |
| Revenue | £58.0 million (2015)[1] |
| £(7.0) million (2015)[1] | |
| £3.7 million (2015)[1] | |
| Website | www.vectura.com |
Vectura Group plc (LSE: VEC) is a British-based pharmaceuticals business. It is based in Chippenham and is a constituent of the FTSE 250 Index.
History
The company was formed in 1997 as a start-up pharmaceuticals business.[2] In 1999 it acquired Co-ordinated Drug Development and the Centre for Drug Formulation Studies.[2] In 2004 it was listed on the Alternative Investment Market.[2] In 2007 it acquired Innovata plc, another developer of pulmonary products,[3] and then moved on the full list of the London Stock Exchange.[2] It acquired Activaero, a German manufacturer in the same sector, for £108 million in March 2014.[4] On 10 June 2016 Vectura completed a merger with Skyepharma; the merged company will continue to be known as Vectura.[5]
Operations
The Group is a developer of inhaled therapies for the treatment of respiratory diseases.[6]
References
- ^ a b c "Annual Report 2015" (PDF). Vectura Group. Retrieved 20 June 2015.
- ^ a b c d "History". Vectura Group. Retrieved 3 August 2016.
- ^ Vectura buys Innovata Guardian, 17 November 2006
- ^ "UK's Vectura buys Activaero for £108 million". Pharma Times. 16 March 2014. Retrieved 20 June 2015.
- ^ "Vectura and Skyepharma to merge in £441m deal". The Telegraph. 16 March 2016. Retrieved 11 June 2016.
- ^ "Dr Karl Keegan to join Vectura Group". Manufacturing chemist. Retrieved 20 June 2015.
